Bethany Templin
Primary Care · Trenton, MINPI 1609259373
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$626
- AbbVie$520
- Pfizer$415
- Novo Nordisk$342
- Johnson & Johnson$300
- Astellas Pharma US Inc$300
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,61298%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $626 |
| AbbVie | 26 | $520 |
| Pfizer | 25 | $415 |
| Novo Nordisk | 22 | $342 |
| Johnson & Johnson | 38 | $300 |
| Astellas Pharma US Inc | 13 | $300 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $247 |
| Corcept Therapeutics | 10 | $221 |
| GSK | 14 | $210 |
| Otsuka America Pharmaceutical, Inc. | 10 | $177 |
| AstraZeneca | 10 | $168 |
| Xeris Pharmaceuticals, Inc. | 6 | $132 |
| E.r. Squibb & Sons, L.L.C. | 7 | $126 |
| Idorsia Pharmaceuticals US Inc | 8 | $121 |
| Boston Scientific | 3 | $111 |
| Exact Sciences | 5 | $89 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Novartis | 3 | $57 |
| Boehringer Ingelheim | 3 | $55 |
| Merck | 3 | $48 |
| Amgen | 2 | $37 |
| Abbott | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $25 |
| Eisai Inc. | 2 | $24 |
| Dexcom, Inc. | 2 | $23 |
| Shield Therapeutics Inc | 1 | $23 |
| Bayer | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$4,711 in reported general payments places this provider in the 90th percentile of 292 primary care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $125,152 |
| EliquisApixaban | 49 | $65,629 |
| JardianceEmpagliflozin | 54 | $62,826 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $53,853 |
| Teriparatide | 12 | $45,857 |
| TrulicityDulaglutide | 21 | $26,059 |
| EntrestoSacubitril/Valsartan | 14 | $23,176 |
| JanuviaSitagliptin Phosphate | 13 | $18,581 |
| MounjaroTirzepatide | 15 | $17,600 |
| MyrbetriqMirabegron | 21 | $15,266 |
| FarxigaDapagliflozin Propanediol | 11 | $11,402 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,687 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,859 |
| Atorvastatin Calcium | 279 | $3,158 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $342 | $125,152102 claims |
| PfizerEliquis | $415 | $65,62949 claims |
| Boehringer IngelheimJardiance | $55 | $62,82654 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $210 | $59,54068 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $626 | $43,66036 claims |
| NovartisEntresto | $57 | $23,17614 claims |
| MerckJanuvia | $48 | $18,58113 claims |
| Astellas Pharma US IncMyrbetriq | $300 | $15,26621 claims |
| AstraZenecaFarxiga | $168 | $11,40211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 primary care providers in Michigan.
Other primary care in Trenton
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
- Katherine HouleMarquette$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.